Equities research analysts expect that PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS – Get Rating) will announce sales of $5.83 million for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for PhaseBio Pharmaceuticals’ earnings, with estimates ranging from $2.50 million to $9.17 million. The firm is expected to issue its next quarterly earnings results on Monday, January 1st.
On average, analysts expect that PhaseBio Pharmaceuticals will report full year sales of $9.56 million for the current fiscal year, with estimates ranging from $500,000.00 to $18.17 million. For the next fiscal year, analysts expect that the business will post sales of $32.97 million, with estimates ranging from $30.49 million to $35.23 million. Zacks’ sales calculations are a mean average based on a survey of analysts that that provide coverage for PhaseBio Pharmaceuticals.
PhaseBio Pharmaceuticals (NASDAQ:PHAS – Get Rating) last posted its quarterly earnings data on Thursday, March 24th. The company reported ($0.90) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.51). The business had revenue of $0.16 million during the quarter, compared to the consensus estimate of $4.92 million.
PHAS stock opened at $1.29 on Friday. PhaseBio Pharmaceuticals has a 1 year low of $0.96 and a 1 year high of $4.24. The firm has a market capitalization of $62.81 million, a PE ratio of -0.43 and a beta of 2.07. The business has a 50 day simple moving average of $1.24 and a 200-day simple moving average of $2.21.
Several hedge funds have recently modified their holdings of PHAS. Parametric Portfolio Associates LLC purchased a new position in shares of PhaseBio Pharmaceuticals during the second quarter worth about $38,000. Raymond James & Associates acquired a new stake in shares of PhaseBio Pharmaceuticals during the 4th quarter valued at approximately $40,000. IPG Investment Advisors LLC purchased a new position in shares of PhaseBio Pharmaceuticals during the 4th quarter worth approximately $76,000. Squarepoint Ops LLC increased its stake in shares of PhaseBio Pharmaceuticals by 29.8% during the 3rd quarter. Squarepoint Ops LLC now owns 27,083 shares of the company’s stock worth $84,000 after purchasing an additional 6,216 shares in the last quarter. Finally, Pura Vida Investments LLC purchased a new position in shares of PhaseBio Pharmaceuticals during the 3rd quarter worth approximately $87,000. 62.38% of the stock is currently owned by institutional investors.
About PhaseBio Pharmaceuticals (Get Rating)
PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure.
- Get a free copy of the StockNews.com research report on PhaseBio Pharmaceuticals (PHAS)
- High-Yield Kinder Morgan Is Still A Buy
- NextEra Energy Offers a Long-Term Gain if You Can Tolerate Short-Term Pain
- Steel Dynamics Scales New Heights On Record Results
- Tesla (NASDAQ: TSLA) Stock Hits Four Figures Once Again
- The Institutions Are Driving Knight-Swift Transportation
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.